Nykode Therapeutics AS (OTCMKTS:VACBF) Short Interest Up 77.3% in March

Nykode Therapeutics AS (OTCMKTS:VACBF) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,887,300 shares, an increase of 77.3% from the February 29th total of 1,064,500 shares. Based on an average daily trading volume, of 4,500 shares, the days-to-cover ratio is currently 419.4 days.

Nykode Therapeutics AS Price Performance

Shares of VACBF remained flat at $1.58 during trading hours on Friday. Nykode Therapeutics AS has a 1-year low of $1.58 and a 1-year high of $2.25. The stock’s 50-day moving average is $1.58 and its 200-day moving average is $1.75.

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10.